The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...
Immutep (IMMP) announces an upcoming poster presentation for the TACTI-004 Phase III trial. The poster will be presented at the European Lung ...
Clinical Trials Arena on MSN3d
MacroGenics axes ADC drug following Phase II failure in prostate cancerThe company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.
The authors recount their discovery of how pathogen-induced interleukin 12 production leads to T H 1 T cell polarization. Simultaneously they discovered the suppressive cytokine interleukin 10 ...
Our reappraisal of sepsis pathophysiology should therefore start by minutely monitoring the immune disorders in the septic patient (including the decrease of monocyte HLA-DR expression) because our ...
Mar. 12, 2025 — Lupus is an autoimmune disease where the body's immune system attacks its own tissues and organs, causing inflammation and damaging organs. A new study has now shown that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback